Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis

A pre-specified meta-analysis of cardiovascular (CV) events from 21 phase 2b/3 dapagliflozin clinical trials was undertaken to characterise the CV profile of dapagliflozin. This showed no increase in CV risk w...

Source: Cardiovascular Diabetology - February 19, 2016 Category: Cardiology Authors: Christian Sonesson, Peter A. Johansson, Eva Johnsson and Ingrid Gause-Nilsson Source Type: research